Visit 360Dx on LinkedIn

Emerging economic and technological trends in the clinical diagnostic market. Diagnostics market and reports on regulatory, reimbursement, and policy issues that impact the commercial operations of clinical labs.

Sister Publication Links
User account menu
Main navigation
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role Premium
With Eye to Future Preparedness, Industry Stakeholders Describe Lessons From COVID-19 Pandemic Premium
FDA, HHS Guidance on COVID-19 LDTs Draws Mixed Reactions from Industry Stakeholders Premium
Notre Dame Team Developing Biosensor to Quickly Diagnose Heart Attack at Point of Care Premium
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders Premium
Netherlands' PamGene Plans to Launch Dx Services for Lung Cancer, Melanoma Treatment Selection Premium
Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business
StageZero Raising C$4.2M in Private Placement of Stocks, Warrants
NGeneBio Gets CE-IVD Mark for HLA Typing Assay
FDA, HHS Guidance on COVID-19 LDTs Draws Mixed Reactions from Industry Stakeholders Premium
DiaSorin, MeMed Obtain CE Mark for High-Throughput Immune-Response Assay
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders Premium
Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role Premium
StageZero Raising C$4.2M in Private Placement of Stocks, Warrants
Netherlands' PamGene Plans to Launch Dx Services for Lung Cancer, Melanoma Treatment Selection Premium
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders Premium
Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business
Notre Dame Team Developing Biosensor to Quickly Diagnose Heart Attack at Point of Care Premium
NGeneBio Gets CE-IVD Mark for HLA Typing Assay
DiaSorin, MeMed Obtain CE Mark for High-Throughput Immune-Response Assay
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role Premium
FDA, HHS Guidance on COVID-19 LDTs Draws Mixed Reactions from Industry Stakeholders Premium
HHS Rule on Dispute Resolution Provisions of Surprise Billing Law Has Labs Concerned Premium
Florida Lab Owner Receives 7 Years in Prison for Role in Kickback Scheme
Florida Healthcare Exec Pleads Guilty to $1.2M Genetic Testing Kickback Scheme
Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business
WHO Inks License Agreement for Commercialization, Manufacturing of COVID-19 Antibody Test Technology
StageZero Raising C$4.2M in Private Placement of Stocks, Warrants
NGeneBio Gets CE-IVD Mark for HLA Typing Assay
DiaSorin, MeMed Obtain CE Mark for High-Throughput Immune-Response Assay
Cowen Initiates Coverage of SomaLogic With Outperform Rating
WHO Inks License Agreement for Commercialization, Manufacturing of COVID-19 Antibody Test Technology
Netherlands' PamGene Plans to Launch Dx Services for Lung Cancer, Melanoma Treatment Selection Premium
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role Premium
DiaSorin, MeMed Obtain CE Mark for High-Throughput Immune-Response Assay
Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business
Footer

1.4330480098724